Advances in cutaneous melanoma.
Clin Transl Oncol
; 14(5): 325-32, 2012 May.
Article
en En
| MEDLINE
| ID: mdl-22551537
After several decades of slow progress in the field of melanoma, significant advances have been reported in recent years. These include a better understanding of the molecular biology of the tumour, a new staging classification system, insights into the patterns of relapse in early stage, and new drugs for the treatment of advanced disease. Ipilimumab and vemurafenib have just been approved and provide a survival benefit in stage IV. Both compounds are under evaluation in the adjuvant setting, where interferon remains the only drug with proven efficacy. Further investigation is required to treat patients with primary or secondary resistance to new drugs.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Cutáneas
/
Melanoma
Límite:
Humans
Idioma:
En
Revista:
Clin Transl Oncol
Año:
2012
Tipo del documento:
Article
País de afiliación:
España
Pais de publicación:
Italia